封面
市场调查报告书
商品编码
1785232

细胞穿透胜肽市场-全球产业规模、份额、趋势、机会和预测,按类型、应用、最终用户、地区和竞争细分,2020-2030 年

Cell Penetrating Peptide Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球细胞穿透胜肽市场价值为 1.3845 亿美元,预计在 2026-2030 年预测期内将以约 10.51% 的惊人速度成长。细胞穿透胜肽 (CPP) 是一类胜肽,已被证实能够将其所连接的分子运送到细胞膜上。因此,增强治疗性蛋白质和胜肽跨细胞膜渗透性的一种有前途的方法是将它们附着到 CPP 上。近年来,细胞穿透胜肽 (CPP) 因其在跨细胞膜输送各种治疗剂方面的巨大潜力而引起了广泛关注。全球细胞穿透胜肽市场正在经历显着成长,这受到塑造该产业格局的几个关键因素的推动。

市场概览
预测期 2026-2030
2024年市场规模 1.3845亿美元
2030年市场规模 2.5274亿美元
2025-2030 年复合年增长率 10.51%
成长最快的领域 肽基CPP
最大的市场 北美洲

关键市场驱动因素

靶向药物传输需求不断增长

主要市场挑战

递送的效率和特异性

主要市场趋势

肽工程的进展

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:全球细胞穿透胜肽市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依类型(蛋白质基CPP、肽基CPP)
    • 依应用(药物传输、基因传递、诊断、分子影像、其他(疫苗开发、抗菌治疗)
    • 按最终用户(製药和生物技术公司、合约研究组织 (CRO)、医院和诊所)
    • 按地区(北美、欧洲、亚太、南美、中东和非洲)
    • 按公司分类(2024)
  • 市场地图
  • 按类型
  • 按应用
  • 按最终用户
  • 按地区

第六章:北美细胞穿透胜肽市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章:欧洲细胞穿透胜肽市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章:亚太细胞穿透胜肽市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章:南美洲细胞穿透胜肽市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章:中东与非洲细胞穿透胜肽市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章:全球细胞穿透胜肽市场:SWOT 分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章:竞争格局

  • The Cupid Peptide Company.
  • AltaBioscience Ltd.
  • AnaSpec Inc.
  • Peptomyc.
  • Amidebio LLC
  • Biopeptide Co LLC
  • AAPPTec
  • CSBio Company Inc
  • CEM Corporation
  • Bachem Holding AG

第 16 章:策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 15901

Global Cell Penetrating Peptide Market has valued at USD 138.45 million in 2024 and is anticipated to grow at an impressive rate of around 10.51% in the forecast period, 2026-2030. Cell-penetrating peptides (CPPs) are a class of peptides that were identified as being capable of transporting the molecules they are linked with across cellular membranes. Therefore, a promising approach for enhancing the permeability of therapeutic proteins and peptides across cellular membranes is by attaching them to a CPP. Cell-penetrating peptides (CPPs) have garnered substantial attention in recent years due to their remarkable potential in delivering various therapeutic agents across cellular membranes. The global cell-penetrating peptides market is experiencing significant growth, driven by several key factors that are shaping the landscape of this industry.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 138.45 Million
Market Size 2030USD 252.74 Million
CAGR 2025-203010.51%
Fastest Growing SegmentPeptide-based CPPs
Largest MarketNorth America

Key Market Drivers

Rising Demand for Targeted Drug Delivery

Targeted drug delivery is transforming modern therapeutics by enhancing treatment efficacy while minimizing side effects. This approach aligns well with the capabilities of cell-penetrating peptides (CPPs), which have emerged as crucial facilitators in the delivery of biologically active molecules across cellular membranes. According to a 2024 study published in Nature Reviews Drug Discovery, over 65% of current pipeline drugs under development aim to incorporate targeted delivery mechanisms. CPPs are increasingly being recognized for their potential to navigate biological barriers and deliver therapeutic agents precisely to disease-affected cells, making them indispensable tools in precision medicine.

A major limitation of conventional drug delivery is nonspecific distribution, which often leads to systemic toxicity and diminished therapeutic outcomes. CPPs address this by enabling selective delivery of therapeutic molecules such as peptides, proteins, and nucleic acids directly to the desired cells or tissues. In fact, recent findings from the Journal of Controlled Release (2023) highlighted that CPPs improved cellular uptake efficiency by over 80% compared to traditional passive delivery systems in preclinical models. This enhanced specificity helps reduce the exposure of healthy tissues to potent therapeutics, thereby mitigating adverse effects and improving patient safety profiles.

Diseases like cancer, neurological disorders, and genetic conditions pose complex delivery challenges due to biological barriers such as the blood-brain barrier (BBB) and cellular membranes. CPPs possess the unique ability to cross these barriers and deliver drugs to previously inaccessible locations. For example, in neuro-oncology research, CPP-modified nanoparticles have demonstrated efficient transport across the BBB, offering promising solutions for treating glioblastoma and other brain cancers. This has accelerated the exploration of CPPs in clinical trials targeting central nervous system (CNS) disorders, where traditional therapies often fail due to poor bioavailability at the target site.

As the push for personalized medicine intensifies, the pharmaceutical and biotech sectors are investing in innovative drug delivery platforms. CPPs offer a flexible platform for delivering a broad spectrum of therapeutics across multiple disease categories. Their compatibility with gene therapy, mRNA delivery, and protein replacement therapies is particularly noteworthy. The growing use of AI-driven peptide design and advanced conjugation techniques is further optimizing CPP-based formulations for clinical use. With increasing validation in translational research, CPPs are poised to play a pivotal role in meeting the global demand for precise and personalized treatment modalities.

Key Market Challenges

Efficiency and Specificity of Delivery

The efficiency of CPP-mediated delivery can vary significantly across different cell types. Achieving consistent and reliable uptake of therapeutic cargoes across diverse cell lines is a complex task. Researchers must optimize CPP sequences and cargoes for each specific cell type of interest, which can be time-consuming and resource-intensive. The type of cargo being delivered plays a crucial role in the efficiency of CPP-mediated delivery. While CPPs are versatile carriers, some cargoes may interact poorly with certain CPPs or their mechanisms of uptake. Ensuring compatibility between CPPs and various therapeutic payloads is a challenge that requires careful consideration. Achieving specificity in delivery is essential to minimize off-target effects on healthy cells and tissues. CPPs must be engineered to ensure that they selectively target disease-associated cells while sparing non-targeted cells. Achieving this level of precision remains a significant challenge and a barrier to clinical adoption. While CPPs often exhibit promising results in vitro, translating their efficacy to in vivo settings can be challenging. Factors such as immune response, tissue distribution, and systemic clearance can affect the performance of CPPs in live organisms, necessitating further research and optimization. Some CPPs have been associated with cytotoxic effects at high concentrations or when used over extended periods. Achieving the right balance between efficient delivery and low toxicity is crucial for the clinical viability of CPP-based therapies. The development of new drug delivery technologies, including CPPs, requires navigating complex regulatory pathways to ensure safety and efficacy. Demonstrating the efficiency and specificity of delivery, as well as addressing potential concerns, is essential for obtaining regulatory approvals. The commercial viability of CPP-based therapies depends on their ability to deliver therapeutic benefits that outweigh the challenges associated with efficiency and specificity. This requires substantial investment in research, development, and clinical validation.

Key Market Trends

Advancements in Peptide Engineering

Advancements in peptide engineering enable the creation of CPPs with specific cellular uptake mechanisms. Researchers can design CPPs that interact favorably with certain types of cells, optimizing cellular uptake efficiency and enhancing the overall efficacy of drug delivery. Through peptide engineering, CPPs can be optimized to deliver a wide range of therapeutic cargoes, including small molecules, peptides, proteins, and nucleic acids. Fine-tuning the interactions between CPPs and cargoes leads to improved delivery efficiency and specificity. Peptide engineering allows for the incorporation of targeting ligands that guide CPPs to specific receptors on target cells. This modification enhances the specificity of drug delivery, reducing off-target effects and minimizing potential side effects. By carefully designing and modifying CPP sequences, researchers can mitigate potential cytotoxic effects associated with some CPPs. This optimization is crucial for ensuring the safety of CPP-based therapies and widening their clinical application. Advances in peptide engineering enable the creation of multi-functional CPPs that can simultaneously deliver therapeutic agents and offer diagnostic capabilities. This innovation is particularly valuable in precision medicine approaches and combination therapies.

Key Market Players

  • The Cupid Peptide Company
  • AltaBioscience Ltd.
  • AnaSpec Inc.
  • Peptomyc SL
  • Amidebio LLC
  • Biopeptide Co LLC
  • AAPPTec
  • CSBio Company Inc
  • CEM Corporation
  • Bachem Holding AG

Report Scope:

In this report, the Global Cell Penetrating Peptide Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Penetrating Peptide Market, By Type:

  • Protein-based CPPs
  • Peptide-based CPPs

Cell Penetrating Peptide Market, By Application:

  • Drug Delivery
  • Gene Delivery
  • Diagnostics
  • Molecular Imaging
  • Others

Cell Penetrating Peptide Market, By End User:

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Hospitals and Clinics

Cell Penetrating Peptide Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Penetrating Peptide Market.

Available Customizations:

Global Cell Penetrating Peptide market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Penetrating Peptide Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Protein-based CPPs, Peptide-based CPPs)
    • 5.2.2. By Application (Drug Delivery, Gene Delivery, Diagnostics, Molecular Imaging, Others (Vaccine development, Antimicrobial Therapy)
    • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Hospitals, and Clinics)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2024)
  • 5.3. Market Map
  • 5.3.1 By Type
  • 5.3.2 By Application
  • 5.3.3 By End User
  • 5.3.4 By Region

6. North America Cell Penetrating Peptide Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell Penetrating Peptide Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Cell Penetrating Peptide Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Cell Penetrating Peptide Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Cell Penetrating Peptide Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Cell Penetrating Peptide Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Cell Penetrating Peptide Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Cell Penetrating Peptide Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Cell Penetrating Peptide Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Cell Penetrating Peptide Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Cell Penetrating Peptide Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cell Penetrating Peptide Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Cell Penetrating Peptide Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Cell Penetrating Peptide Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Cell Penetrating Peptide Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Cell Penetrating Peptide Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Cell Penetrating Peptide Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cell Penetrating Peptide Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Cell Penetrating Peptide Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Cell Penetrating Peptide Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Cell Penetrating Peptide Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cell Penetrating Peptide Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Cell Penetrating Peptide Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Cell Penetrating Peptide Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Cell Penetrating Peptide Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. The Cupid Peptide Company.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. AltaBioscience Ltd.
  • 15.3. AnaSpec Inc.
  • 15.4. Peptomyc.
  • 15.5. Amidebio LLC
  • 15.6. Biopeptide Co LLC
  • 15.7. AAPPTec
  • 15.8. CSBio Company Inc
  • 15.9. CEM Corporation
  • 15.10. Bachem Holding AG

16. Strategic Recommendations

17. About Us & Disclaimer